BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31597100)

  • 1. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.
    Mills BN; Connolly KA; Ye J; Murphy JD; Uccello TP; Han BJ; Zhao T; Drage MG; Murthy A; Qiu H; Patel A; Figueroa NM; Johnston CJ; Prieto PA; Egilmez NK; Belt BA; Lord EM; Linehan DC; Gerber SA
    Cell Rep; 2019 Oct; 29(2):406-421.e5. PubMed ID: 31597100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
    Sanders KL; Fox BA; Bzik DJ
    Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
    Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
    Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation and Local Anti-CD40 Generate an Effective
    Yasmin-Karim S; Bruck PT; Moreau M; Kunjachan S; Chen GZ; Kumar R; Grabow S; Dougan SK; Ngwa W
    Front Immunol; 2018; 9():2030. PubMed ID: 30245691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
    Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
    Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
    Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.
    Ye J; Mills BN; Zhao T; Han BJ; Murphy JD; Patel AP; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    Cancer Immunol Res; 2020 Jan; 8(1):94-107. PubMed ID: 31719057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
    Sabel MS; Arora A; Su G; Griffith KA; Mathiowitz E; Reineke JJ; Chang AE
    J Immunother; 2007; 30(8):808-16. PubMed ID: 18049332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
    Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
    Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
    Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
    Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer.
    Stump CT; Roehle K; Manjarrez Orduno N; Dougan SK
    Open Biol; 2021 Nov; 11(11):210245. PubMed ID: 34784792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.